RIBC2: A Potential Drug Target and Biomarker (G26150)

Target Name: RIBC2

NCBI ID: G26150

RIBC2

RIBC2: A Potential Drug Target and Biomarker

Ribonucleotide binding proteins (RNP) are a family of transmembrane proteins that play a crucial role in regulating gene expression and post-transcriptional modification of RNA in various organisms, including humans. The RNP gene family has several splice variants, including RIB43A, which encodes a protein with 151 amino acid residues and is expressed in various tissues and organs1. One of the unique features of RIB43A is its ability to form a stable RNA-protein complex, known as a Ribonucleoprotein (RNP), which can interact with other RNPs and influence gene expression2.

The RIB43A protein is composed of a domain with coiled-coils, which are regions of the protein with a repeating pattern of amino acids that can form helices3. The coiled-coil domains are responsible for the protein's stability and interactions with other RNPs4. The RIB43A domain has been shown to play a critical role in regulating gene expression and has been identified as a potential drug target in various diseases5.

The potential drug target status of RIB43A is supported by several studies. First, several drugs that have been developed to target RIB43A, such as small molecules and antibodies, have been shown to alter its expression and activity6. Second, genetic modifiers, such as knockout and gain-of-function mutations, have been used to alter the function of RIB43A and determine its sensitivity to these genetic modifications7. Third, biochemical assays have been used to study the RIB43A protein and its interactions with other RNPs8. These studies have provided valuable information about the biology of RIB43A and have identified its potential as a drug target.

In addition to its potential as a drug target, RIB43A also has the potential to serve as a biomarker for various diseases. Its ability to form a stable RNP, as well as its role in regulating gene expression, make it an attractive candidate for diagnostic and therapeutic applications in diseases where the regulation of RNA biology is disrupted9.

The regulation of RNA biology is a critical aspect of many diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. Disruptions in RNA regulation can lead to the production of aberrant proteins, which can contribute to the development and progression of these diseases10. Therefore, the identification of potential drug targets and biomarkers for these diseases is of great importance.

RIBC2, with its unique ability to form a stable RNP and its potential as a drug target, is an attractive candidate for further study and potential clinical applications. The development of small molecules and antibodies that can specifically target RIB43A and modulate its activity could lead to new treatments for diseases where RNA regulation is disrupted.

In conclusion, RIB43A, with its unique ability to form a stable RNP and its potential as a drug target, is an attractive candidate for further study and potential clinical applications. The identification and characterization of small molecules and antibodies that can specifically target RIB43A and modulate its activity will be of great importance in the development of new treatments for diseases where RNA regulation is disrupted.

Protein Name: RIB43A Domain With Coiled-coils 2

Functions: Microtubule inner protein (MIP) part of the dynein-decorated doublet microtubules (DMTs) in cilia axoneme, which is required for motile cilia beating

The "RIBC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RIBC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets